Pearl E. Grimes, MD

Discussing Colorism and Pigmentary Disorders, With Seemal Desai, MD, and Pearl Grimes, MD

 podcast, hosted by Skin of Color Society (SOCS) leaders and produced by 

, Seemal R. Desai, MD, sat down with internationally recognized pigmentary disorders expert Pearl Grimes, MD, for a wide-ranging discussion on colorism, pigmentary disease, and the ethical complexities dermatologists face when treating patients seeking skin lightening.

Desai opened the conversation by emphasizing the growing importance of understanding the intersection between pigmentary disorders and cultural perceptions of skin tone, noting that issues surrounding skin bleaching, fairness, and hyperpigmentation remain deeply intertwined in many societies. Grimes, founder of the Vitiligo and Pigmentation Institute of Southern California and the Pearl Melasma Research and Treatment Institute, reflected on more than 45 years of experience in pigmentation research, describing the field as both her professional passion and a core part of her identity.

Throughout the discussion, Grimes highlighted the global nature of colorism, explaining that preference for lighter skin extends across numerous cultures and geographic regions, including the US, Europe, Africa, the Middle East, and Asia. She noted that the roots of colorism are multifactorial, shaped in some regions by colonialism and enslavement, while in others influenced more heavily by class structures and social hierarchy. According to Grimes, lighter skin has historically been associated with economic opportunity, professional advancement, marriage prospects, and social status in many cultures.
Desai added personal perspective by referencing the longstanding caste system in India, where lighter skin historically carried social advantages tied to education, employment, and marriage. He noted that these attitudes have persisted across generations and remain influential today despite evolving societal norms.

The conversation then shifted toward the clinical realities dermatologists encounter when managing disorders such as melasma, post-inflammatory hyperpigmentation, and lichen planus pigmentosus. Both physicians acknowledged that the distinction between medically treating uneven pigmentation and addressing culturally driven desires for lighter skin can become blurred in practice.

Grimes explained that many patients initially present seeking treatment for a specific pigmentary condition, but underlying concerns related to colorism may emerge during the clinical encounter. She described how some individuals hope treatment of hyperpigmentation will also lead to an overall lighter complexion, whether consciously or subconsciously motivated by societal pressures.

Both speakers emphasized the responsibility of dermatologists to navigate these conversations thoughtfully and ethically. Grimes stressed the importance of helping patients achieve healthy, even skin tone while also reinforcing positive self-image and discouraging aggressive skin-lightening practices that may carry long-term risks. She noted that clinicians must balance medical management with emotional and psychological support, encouraging patients to focus on becoming “the best version” of themselves rather than pursuing unrealistic or potentially harmful standards tied to colorism.

Editor’s note: This description was summarized with the help of AI tools.

Desai S, Grimes P. Skin of Color Savvy: Tackling Colorism in Dermatology, With Seemal Desai, MD, and Pearl Grimes, MD. HCPLive. March 24, 2026. Accessed May 12, 2026. 

https://www.hcplive.com/view/skin-of-color-savvy-tackling-colorism-dermatology-seemal-desai-md-pearl-grimes-md

Videos

Seemal R. Desai, MD, and Pearl E. Grimes, MD, discuss the complexities of colorism and its impact on pigmentary disorders.

Skin of Color Savvy: The Art and Science of Treating Patients of Color

Skin of Color Savvy: Tackling Colorism in Dermatology, With Seemal Desai, MD, and Pearl Grimes, MD

, Seemal Desai, MD, past president of SOCS, is joined by Pearl Grimes, MD, a globally recognized expert in vitiligo and pigmentary disorders and founder of the Vitiligo and Pigmentation Institute of Southern California. Together, they engage in a nuanced discussion on colorism, its historical roots, and its intersection with the clinical management of pigmentary disorders.

The conversation begins with an exploration of colorism as a global phenomenon, emphasizing its presence across regions including the United States, Africa, Asia, and Europe. Grimes highlights the complex historical and sociocultural factors underlying colorism, including colonialism, class structures, and longstanding societal preferences for lighter skin tones. These influences, the experts note, extend beyond aesthetics, impacting socioeconomic mobility, professional opportunities, and interpersonal relationships.

Desai and Grimes then transition to the clinical implications of colorism, particularly in dermatology practices focused on treating hyperpigmentation. They discuss how patient motivations for seeking treatment may reflect a combination of medical concerns and deeper sociocultural influences. Conditions such as melasma, post-inflammatory hyperpigmentation, and lichen planus pigmentosus are frequently treated in clinical settings, but patient expectations may extend beyond restoring even skin tone to a desire for overall skin lightening. The speakers emphasize the importance of distinguishing between appropriate medical treatment and requests influenced by colorism-driven preferences.

A significant portion of the discussion centers on the ethical and clinical challenges dermatologists face in navigating these blurred boundaries. Both experts underscore the importance of patient-centered communication, advocating for approaches that validate patient concerns while reinforcing the goal of restoring natural skin tone rather than altering inherent pigmentation. They stress the need for dermatologists to address the psychological and emotional dimensions of pigmentary disorders, particularly as they relate to self-perception and societal pressures.

The episode also highlights the widespread use of unregulated skin-lightening products and the associated health risks. Desai and Grimes discuss the global prevalence of over-the-counter products containing harmful agents such as high-potency topical steroids, mercury, and arsenic, often marketed as cosmetic or “brightening” treatments. They further address emerging trends, including intravenous and oral glutathione use for skin lightening, noting documented risks such as severe adverse reactions and potential links to disease exacerbation. These examples underscore the critical need for clinicians to conduct thorough patient histories and proactively inquire about all skincare products and treatments.

Education and advocacy emerge as central themes throughout the latter portion of the discussion. The speakers emphasize the role of dermatologists in educating patients about safe and evidence-based treatments, as well as the broader responsibility to engage in public health messaging. They also highlight the importance of regulatory efforts to limit the availability of harmful products and the need for continued collaboration with organizations such as the Skin of Color Society and other global advocacy groups.

The episode concludes with a call to action for dermatologists to approach pigmentary disorders with both clinical rigor and cultural awareness. By addressing the medical, psychological, and societal dimensions of colorism, clinicians can better support patients while promoting safe practices and advancing equitable dermatologic care.

To learn more about SOCS’s programs and initiatives, visit 

Editor’s note: This summary was edited with the help of AI tools.

Podcasts

In this episode of the Skin of Color Savvy podcast, 2 leaders in dermatology discuss the complexities of colorism and its impact on pigmentary disorders.

Iltefat Hamzavi, MD, explores key areas of patient communication that may shape adherence and outcomes in patients with vitiligo.

Communication With Patients With Vitiligo

Seemal R. Desai, MD, examines the mechanisms of JAK inhibitors and why these agents play an important role in the treatment of vitiligo.

Pearl E. Grimes, MD

Articles